Harmony Biosciences Holdings, Inc.

Harmony Biosciences plans to accelerate Phase III development of a high-dose pitolisant formulation (pitolisant HD) in idiopathic hypersomnia (IH) after the US Food and Drug Administration turned down

Harmony Biosciences plans to accelerate Phase III development of a high-dose pitolisant formulation (pitolisant HD) in idiopathic hypersomnia (IH) after the US Food and Drug Administration turned down

“How does it feel that you have a billion-dollar neuroscience commercial business, and no one cares?” That’s the question an investor asked Alkermes’ chief operating officer Blair Jackson at the recen

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol Looks Into Tolerizing Vaccines,